CA3175921A1 - Canine antibody variants - Google Patents

Canine antibody variants

Info

Publication number
CA3175921A1
CA3175921A1 CA3175921A CA3175921A CA3175921A1 CA 3175921 A1 CA3175921 A1 CA 3175921A1 CA 3175921 A CA3175921 A CA 3175921A CA 3175921 A CA3175921 A CA 3175921A CA 3175921 A1 CA3175921 A1 CA 3175921A1
Authority
CA
Canada
Prior art keywords
antibody
igg
constant domain
canine
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3175921A
Other languages
English (en)
French (fr)
Inventor
Lisa Marie BERGERON
Henry Luis CAMPOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of CA3175921A1 publication Critical patent/CA3175921A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3175921A 2020-04-17 2021-04-16 Canine antibody variants Pending CA3175921A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011453P 2020-04-17 2020-04-17
US63/011,453 2020-04-17
PCT/US2021/027836 WO2021212081A1 (en) 2020-04-17 2021-04-16 Canine antibody variants

Publications (1)

Publication Number Publication Date
CA3175921A1 true CA3175921A1 (en) 2021-10-21

Family

ID=75888187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3175921A Pending CA3175921A1 (en) 2020-04-17 2021-04-16 Canine antibody variants

Country Status (17)

Country Link
US (2) US20230242635A1 (cg-RX-API-DMAC10.html)
EP (1) EP4136106A1 (cg-RX-API-DMAC10.html)
JP (2) JP7879810B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230005156A (cg-RX-API-DMAC10.html)
CN (1) CN115996949A (cg-RX-API-DMAC10.html)
AU (1) AU2021256056A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022020944A2 (cg-RX-API-DMAC10.html)
CA (1) CA3175921A1 (cg-RX-API-DMAC10.html)
CL (2) CL2022002857A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022014695A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP22080846A (cg-RX-API-DMAC10.html)
IL (1) IL297287A (cg-RX-API-DMAC10.html)
MX (1) MX2022012866A (cg-RX-API-DMAC10.html)
PE (1) PE20230108A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022552742A1 (cg-RX-API-DMAC10.html)
TW (1) TW202204403A (cg-RX-API-DMAC10.html)
WO (1) WO2021212081A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
CN120005022A (zh) 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗il31抗体
JP7832123B2 (ja) 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
CA3194936A1 (en) * 2020-09-28 2022-03-31 Zoetis Services Llc Canine antibody variants
AU2023289332A1 (en) * 2022-06-21 2024-12-12 Zoetis Services Llc Canine antibody mutants
US20240254231A1 (en) 2023-01-20 2024-08-01 PetMedix Ltd. Therapeutic antibodies
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
JP5833145B2 (ja) * 2011-02-04 2015-12-16 ゾエティス・エルエルシー 免疫原性bordetellabronchiseptica組成物
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
PE20181336A1 (es) 2015-09-18 2018-08-21 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
CN116271014A (zh) * 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
EP3526246A1 (en) * 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
US10093731B2 (en) * 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
EP3866842A4 (en) 2018-10-18 2022-07-13 Kindred Biosciences, Inc. FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE
CN120005022A (zh) * 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
KR20220066002A (ko) * 2019-03-20 2022-05-23 킨드레드 바이오사이언시스, 인코포레이티드 의학적 용도의 ngf 길항제
CA3194936A1 (en) * 2020-09-28 2022-03-31 Zoetis Services Llc Canine antibody variants
MX2023008785A (es) * 2021-01-28 2023-12-14 Zoetis Services Llc Mutaciones en regiones constantes de anticuerpos caninos.

Also Published As

Publication number Publication date
PE20230108A1 (es) 2023-01-25
CL2023003377A1 (es) 2024-04-19
JP2023522029A (ja) 2023-05-26
KR20230005156A (ko) 2023-01-09
TW202204403A (zh) 2022-02-01
ECSP22080846A (es) 2023-02-28
US20230242635A1 (en) 2023-08-03
CO2022014695A2 (es) 2022-10-21
PH12022552742A1 (en) 2024-03-25
WO2021212081A1 (en) 2021-10-21
CL2022002857A1 (es) 2023-06-02
JP2026097964A (ja) 2026-06-16
IL297287A (en) 2022-12-01
AU2021256056A1 (en) 2022-10-20
JP7879810B2 (ja) 2026-06-24
US20260193342A1 (en) 2026-07-09
CN115996949A (zh) 2023-04-21
MX2022012866A (es) 2022-11-08
EP4136106A1 (en) 2023-02-22
BR112022020944A2 (pt) 2022-12-27

Similar Documents

Publication Publication Date Title
US20230242635A1 (en) Canine antibody variants
US20250026834A1 (en) Feline antibody variants
US12612454B2 (en) Canine antibody variants
EP4512416A2 (en) Mutations in canine antibody constant regions
US20240400708A1 (en) Mutations in feline antibody constant regions
US12612455B2 (en) Feline antibody variants
RU2840969C1 (ru) Варианты кошачьих антител
HK40121344A (en) Mutations in canine antibody constant regions
BR122024006370A2 (pt) Polipeptídeo, seu uso, composição farmacêutica, kit, igg modificada, vetor, célula isolada, molécula de fusão, e seu método de fabricação

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220916

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250331

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250613

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250616

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250620

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250620

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260318

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260318

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260608